The estimated Net Worth of Bio Pharma Holdings, Ltd. C... is at least $10.7 Million dollars as of 28 July 2009. Bio C owns over 1,250,000 units of Cortexyme Inc stock worth over $3,806,839 and over the last 15 years Bio sold CRTX stock worth over $6,875,000.
Bio has made over 1 trades of the Cortexyme Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Bio sold 1,250,000 units of CRTX stock worth $6,875,000 on 28 July 2009.
The largest trade Bio's ever made was selling 1,250,000 units of Cortexyme Inc stock on 28 July 2009 worth over $6,875,000. On average, Bio trades about 1,250,000 units every 0 days since 2009. As of 28 July 2009 Bio still owns at least 1,952,225 units of Cortexyme Inc stock.
You can see the complete history of Bio C stock trades at the bottom of the page.
Bio's mailing address filed with the SEC is 2000 REGENCY PARKWAY, SUITE 255, CARY, NC, 27518.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: